Transaction DateRecipientSharesTypePriceValue
Neurotrope
Neurotrope logo

Neurotrope, Inc. engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease.

Ticker: NTRP
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1513856
Employees: 7
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $30 M (0%)
Assets, Current: $31 M (72%)
Property, Plant and Equipment, Net: $25 Th (13%)
Assets: $31 M (72%)
Accounts Payable, Current: $968 Th (134%)
Accrued Liabilities, Current: $100 Th (51%)
Liabilities, Current: $1 M (122%)
Common Stock, Value, Issued: $2 Th (81%)
Common Stock, Shares, Issued: $24 M (81%)
Retained Earnings (Accumulated Deficit): $94 M (6%)
Stockholders' Equity (Parent): $30 M (0%)
Liabilities and Equity: $31 M (72%)
Research and Development: $438 Th (-26%)
General and Administrative Expenses: $2 M (-45%)
Income before taxes: $3 M (-46%)